J Hematol Oncol. 2010 Feb 11;3:8.

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Source

Institut de Recherche en Immunologie et Cancérologie and Department of Pharmacology, Université de Montréal, Montreal, Quebec H3C 3J7, Canada.

Abstract

The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival. Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases or gain-of-function mutations in RAS or RAF genes. Components of the ERK1/2 pathway are therefore viewed as attractive candidates for the development of targeted therapies of cancer. In this article, we briefly review the basic research that has laid the groundwork for the clinical development of small molecules inhibitors of the ERK1/2 pathway. We then present the current state of clinical evaluation of MEK1/2 inhibitors in cancer and discuss challenges ahead.

PMID:: 20149254; [PubMed - indexed for MEDLINE]
PMCID: PMC2830959

Free PMC Article

Images from this publication.See all images (4) Free text

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Education

New England Research Institutes Inc.

Medical

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy. [Cancer Res. 2009]
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S, Wang H, Li WH, Higgins B, Kolinsky K, Packman K, Specian A Jr, Kong N, Huby N, Wen Y, et al. Cancer Res. 2009 Mar 1; 69(5):1924-32. Epub 2009 Feb 24.
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. [Int J Cancer. 2009]
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Int J Cancer. 2009 Nov 15; 125(10):2332-41.
Review Targeting the ERK signaling pathway in cancer therapy. [Ann Med. 2006]
Review Targeting the ERK signaling pathway in cancer therapy.
Kohno M, Pouyssegur J. Ann Med. 2006; 38(3):200-11.
cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner. [Oncogene. 2002]
cAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1/2 in a PKA-independent manner.
Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F. Oncogene. 2002 Sep 5; 21(39):6101-12.
Review Novel mitogen-activated protein kinase kinase inhibitors. [Expert Opin Investig Drugs. 2011]
Review Novel mitogen-activated protein kinase kinase inhibitors.
Chapman MS, Miner JN. Expert Opin Investig Drugs. 2011 Feb; 20(2):209-20.

See reviews... See all...

Cited by 6 PubMed Central articles

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. [J Hematol Oncol. 2011]
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. J Hematol Oncol. 2011 Nov 14; 4:46. Epub 2011 Nov 14.
Impact of bile acids on the growth of human cholangiocarcinoma via FXR. [J Hematol Oncol. 2011]
Impact of bile acids on the growth of human cholangiocarcinoma via FXR.
Dai J, Wang H, Shi Y, Dong Y, Zhang Y, Wang J. J Hematol Oncol. 2011 Oct 12; 4:41. Epub 2011 Oct 12.
Therapeutic strategies for targeting ras proteins. [Genes Cancer. 2011]
Therapeutic strategies for targeting ras proteins.
Gysin S, Salt M, Young A, McCormick F. Genes Cancer. 2011 Mar; 2(3):359-72.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

From basic research to clinical development of MEK1/2 inhibitors for cancer ther...
From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.
J Hematol Oncol. 2010 Feb 11 ;3:8.

PubMed
Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia...
Regulation of cell cycle transition and induction of apoptosis in HL-60 leukemia cells by lipoic acid: role in cancer prevention and therapy.
J Hematol Oncol. 2008 May 30 ;1:4.

PubMed
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubici...
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
J Hematol Oncol. 2010 Mar 11 ;3:9.

PubMed
Aggressive juvenile fibromatosis of the paranasal sinuses: case report and brief...
Aggressive juvenile fibromatosis of the paranasal sinuses: case report and brief review.
J Hematol Oncol. 2008 May 28 ;1:3.

PubMed
Treatment of multicentric Castleman's Disease accompanying multiple myeloma with...
Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
J Hematol Oncol. 2009 Apr 28 ;2:19.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Education

Medical

Libraries

Supplemental Content

Related citations

Cited by 6 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information